Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
AssigneeIntellect Neurosciences Inc.
InventorDaniel G. Chain
Life of this patent
Estimating the term…
Loading patent…
AssigneeIntellect Neurosciences Inc.
InventorDaniel G. Chain
Estimating the term…
The invention relates to methods of treating a subject having Alzheimer's Disease, comprising the step of administering an antibody molecule which is targeted to β amyloid peptide or to fragment thereof. In another embodiment the invention relates to methods of treating a disease or a disorder, characterized by amyloid beta deposition. In another embodiment, the invention relates to an antibody molecule, which is free end-specific for the N-terminus or the C-terminus of an amyloid β peptide and to a pharmaceutical composition thereof. In another embodiment, the invention relates to an antibody molecule, which is targeted to the free C or N-terminus of a N-and/or C-terminus truncated amyloid β peptide fragment.
A method of treating a subject having Alzheimer's Disease, comprising the step of administering an antibody which is targeted to amyloid β peptide, or to fragment thereof, thereby treating the subject having Alzheimer's Disease.
A method of treating a subject having a disease or disorder characterized by amyloid beta deposition, comprising the step of administering an antibody which is targeted to amyloid β peptide, or to fragment thereof, thereby treating the subject having disease or disorder characterized by amyloid beta deposition.
A method for delaying or inhibiting or suppressing the accumulation of an amyloid β peptide or fragment thereof, comprising the step of administering an antibody which is targeted to an amyloid β peptide, or to fragment thereof, thereby delaying or inhibiting or suppressing accumulation of amyloid β peptide or fragment thereof in the brain.
A method for delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof, comprising the step of administering at antibody which is targeted to amyloid β peptide, or fragment thereof, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof.
An antibody that is free-end specific and is targeted to the free N-terminus of amyloid β-peptide.
A antibody that is free-end specific and is targeted to the free N-terminus of amyloid β-peptide, wherein the first amino acid of amyloid β-peptide of said is aspartate.
An antibody that is free-end specific and is targeted to the free N terminus of N and/or C-terminus-truncated amyloid β peptide fragment.
An antibody that is free-end specific and is targeted to the free C-terminus of the amyloid β-peptide Aβ1-39, Aβ1-40, Aβ1-41, or Aβ1-43.
An antibody that is free-end specific and is targeted to the free C-terminus of N- and/or C-terminus-truncated amyloid β peptide fragment.
A single chain or artifcial antibody that is free-end specific and is targeted to the free C-terminus of the amyloid β-peptide Aβ1-42.
Dependencies are inferred from the claim text.